Division of Compensation Analysis and 

Support

Program Evaluation Report

Document Number: DCAS-PER-058

Effective Date: 11/21/2014

Revision No. 0

Dow Chemical Co. (Madison Site) Page 1 of 2

Author: Signature on file Date: 11/21/2014 

 Dave Allen, HP Team Leader

Approval: Signature on file Date: 11/21/2014

 J.W. Neton, Associate Director for Science

Supersedes: None

RECORD OF ISSUE/REVISIONS

ISSUE 

AUTHORIZATION 

DATE

11/21/2014

EFFECTIVE 

DATE

11/21/2014

REV. NO. 

0

DESCRIPTION

New document to determine the effect 

on previously completed claims due to a 

revision to the Dow Chemical appendix.

1.0 Description

On 4/3/2014 revision 1 of Battelle-TBD-6000 Appendix C, Dow Chemical Co. (Madison 

Site) was issued. Both revision 0 and revision 1 of the appendix provided a prescriptive 

dose estimate to be used for employees of the Dow Chemical site in Madison Illinois 

(Dow). 

2.0 Issue Evaluation

The revision to appendix C was based on revisions to Battelle-TBD-6000 and ORAUTOTIB-70. One of the changes to TBD-6000 was the deposition time used to calculate 

external dose from contamination. This value was changed from 7 days to 30 days 

causing an increase in the photon dose from this exposure. Another change was the 

inclusion of beta dose from contamination that was not included in the previous revision. 

ORAUT-OTIB-70 provides a depletion rate for residual contamination after operations 

end. A revision to OTIB-70 on 3/5/2012 reduced that depletion rate and thus increased 

doses in the residual period.

Together these result in at least some increased dose for all cases in the operational and 

residual period.

3.0 Plan for Resolution or Corrective Action

All Dow claims completed prior to 4/3/2014 with a probability of causation (POC) less 

than 50% were included in the affected population of claims for this PER. This totals 96

claims however, during this evaluation, 3 of the claims were returned to NIOSH for other 

reasons. Those claims will be reworked using revision 1 of the Appendix C so no further 

evaluation under this PER is necessary. Also, 13 claims also had employment at General 

Steel Industries (GSI). These claims will be evaluated under PER-0057 (GSI) which 
Division of Compensation Analysis and 

Support

Program Evaluation Plan

Document Number: DCAS-PER-058

Effective Date: 11/21/2014 Revision No. 0 Page 2 of 2

includes revising dose estimate for Dow per revision 1 of Appendix C. Therefore, no 

further revaluation of those 13 claims was necessary under this PER.

The dose for each of the remaining 80 cases was recalculated using revision 1 of 

Appendix C as well as the current revision of any other applicable documents. 77 of 

these claims resulted in a POC below 45% while none resulted in a POC above 50%. For 

the remaining 3 claims, IREP was ran 30 times at 10,000 iterations per NIOSH 

procedures and the resulting POC less than 50% for the each of the 3 claims.

NIOSH will provide the Department of Labor with the list of all the claims evaluated under 

this PER. Since none of the claims resulted in a POC greater than 50%, NIOSH will not 

request the return of any of the claims.